CPHI & PMEC China 2026 success unlocks fresh investment and partnership prospects for Greater Bay Area and Asian pharma firms
Executive summary: CPHI & PMEC China 2026 exhibition concluded in June 2026 with record attendance, fostering pharmaceutical supply‑chain connections; concurrently Akeso dosed the first patient in a Phase II study of its TROP2/Nectin‑4 bispecific ADC (AK146D1) combined with Ivonescimab for advanced NSCLC on July 20, 2026. The exhibition signals renewed momentum for Greater Bay Area and Asian pharma sectors, while the Akeso trial highlights advancing biotech innovation that could attract further investment and partnership interest.
Who is involved: CPHI & PMEC China organizers, pharmaceutical manufacturers and suppliers, and Akeso Inc. (ticker 9926.HK) with its clinical partners.
Likely next: Stakeholders expect follow‑up partnership announcements from the exhibition and anticipate interim data read‑outs from Akeso’s Phase II study later in 2026.
The CPHI & PMEC China exhibition held in June 2026 attracted an unprecedented number of industry professionals, strengthening connections across the pharmaceutical supply chain. Organizers say the event’s momentum is shifting focus toward the Greater Bay Area and broader Asia‑Pacific pharma markets, where new collaboration opportunities are emerging. A parallel announcement from Akeso showing the first‑patient dose in a Phase II bispecific ADC trial underscores the region’s growing innovation pipeline.
Timeline
- — Fostering new opportunities in the Greater Bay Area and Asia's Pharmaceutical Industry (PR Newswire)
- — Akeso Doses First Patient in Phase II Study of Novel TROP2/Nectin-4 Bispecific ADC (AK146D1) in Combination with Ivonescimab for Advanced NSCLC (PR Newswire)
Analysis — what this means
Likely next events
- Akeso dosed first patient in Phase II study AK146D1-201 on July 20, 2026
- CPHI & PMEC China 2026 event concluded in June 2026 (as reported)
Sectors affected
- Pharmaceutical manufacturing
- Biotechnology R&D
- Greater Bay Area life sciences sector
Sources
- Fostering new opportunities in the Greater Bay Area and Asia's Pharmaceutical Industry — PR Newswire
- Akeso Doses First Patient in Phase II Study of Novel TROP2/Nectin-4 Bispecific ADC (AK146D1) in Combination with Ivonescimab for Advanced NSCLC — PR Newswire
Related cases
- Asian markets rise as a chip‑sector rally lifts the Nikkei, reinforcing regional equity strength
- Easing US rate‑hike fears lift Asian equities, with the yen strengthening as Fed commentary dampens tightening expectations
- Thai team’s drone‑mounted bionic eagle‑claw gripper for disaster relief reaches the Lancang‑Mekong science finals, spotlighting regional rescue‑robotics advances
- Sivers Semiconductors commits $30 million to boost European InP photonics output for AI data‑center demand
- Asian equities edge higher as investors await key US labor market data
- Clarins taps Chinese star Zhang Ziyi as global ambassador for its Precious line to strengthen its foothold in the Asian luxury beauty market